Midgard Science

3billion

Seoul, South Korea3billion.ioFrom their website, Nov 2026

  • CLIA

Work here? Claim this listing

About

3billion provides rare disease genetic diagnostic services and newborn genetic screening services. It serves patients, families, clinicians, and partners from its site in Seoul, South Korea, with support for customers around the world.

Services

  • 3B-GENOME

    Whole-genome sequencing-based genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.

  • 3B-EXOME

    Exome-focused genetic testing for rare disease diagnosis, with automated reanalysis and raw data included.

  • 3B-VARIANT

    Sanger sequencing to confirm a specific variant in a patient or family member.

  • 3B-INTERPRETER

    Genomic data analysis and interpretation service for user-generated FASTQ data, with a clinical report.

  • GEBRA™

    Variant interpretation and diagnosis platform that turns VCF data into a final clinical report.

  • Reanalysis

    Automatic reanalysis of previously undiagnosed rare disease cases using updated databases, AI, and expert review.

  • Drug discovery

    AI-based drug discovery work for rare diseases, including target discovery, pocket discovery, and compound design.

  • Newborn genetic screening

    Genetic screening services for newborns, as named in the service terms.

3 more services
  • 3B-NEO
  • EVIDENCE
  • 3Cnet
Turnaround
  • 1 day to 4 weeks
  • Initial response within one business day
  • EVIDENCE classifies ~100,000 WES variants in 5 minutes on average
What to send
  • FASTQ data
  • Blood
  • Saliva
  • Other specimens
  • Sample kit included for ordering
  • Biological samples such as blood, saliva, or other specimens

Capabilities

Assays and studies
  • Rare disease genetic testing
  • Variant interpretation
  • Reanalysis
  • Genomic data analysis
  • Sanger confirmation
  • Newborn genetic screening
3 more
  • WGS
  • WES
  • Pathogenicity prediction
Scale and capacity
  • 70+ countries where testing is available
  • 2,200+ clinicians who have used their testing
  • 100,000+ patients who have received test results
  • 62,000+ patients' genomes tested
  • 40,000+ patients' genomes tested
  • 20,000+ patients' genomes tested
  • 2,200+ clinicians who have used the testing
  • 12+ global pharma partners
Therapeutic areas
  • Rare diseases
  • Reproductive loss
  • Fetal death
  • Inherited risk
  • Orphan drugs

Instruments and platforms

  • Illumina NovaSeq X

Modalities and species

Modalities
Small molecule
Species and models
  • Human
  • Illumina NovaSeq X

Certifications

As the company states them, with the certificate or registry record where there is one.

  • CLIASelf-reported

    As listed: CLIA (ID # 99D2274041); CLIA certified

  • CAPSelf-reported

    As listed: CAP (License # 8750906); CAP accredited

Industries served

  • Pharma
  • Rare disease diagnostics

Details

Founded
2016
Based in
Seoul, South Korea
Serves
Worldwide, 70+ countries
General contact
support@3billion.io on their site
Phone
+82-2-6258-3770

Similar labs